An observational study in Intracerebral Hemorrhage, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Emory University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Cerebral Hemorrhage with a site in United States — 31 open to participants now, 42 under way, 6 of them phase 3. Cerebral Hemorrhage · United States.
Among the 109 studies in Cerebral Hemorrhage with a site in United States, this one is the 6th largest by planned enrollment of the 38 observational ones that give a count, is one of 10 that started in 2026, is one of 38 observational ones, reaches primary completion later than 40 of the 41 other live ones, and was the 105th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →31 of the 109 studies in Cerebral Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–80
Massachusetts General Hospital · Sites in United States
Ages 18–99
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 24 · Phase 3 10 · Phase 4 3
First in 1993; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 300 across 181 observational studies indexed under Cerebral Hemorrhage.
Median enrollment 60 across the 71 interventional studies, 245 across the 38 observational. Of the 61 that completed or were terminated, 28 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 109 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 3 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
12 of the studies in Cerebral Hemorrhage with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT05020535Johns Hopkins UniversityBiomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) | 2026-11-30 |
| NCT06632587Thomas Jefferson UniversityTiming Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes | 2026-12-01 |
| NCT06725108University of ChicagoHemodynamic ABI Monitor | 2026-12-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 109 studies in Cerebral Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to quantify the real-world effect of minimally invasive surgery (MIS) in patients with acute spontaneous supratentorial intracerebral hemorrhage.
Intracerebral hemorrhage (ICH) is one of the most severe forms of stroke, accounting for nearly one-third of all strokes worldwide and affecting more than 3 million people annually. It remains associated with high mortality-over 40% of patients die within 30 days-and significant long-term disability among survivors. Basal ganglia hemorrhage is the most common location of spontaneous ICH and often results in profound neurological deficits, including weakness, sensory loss, visual impairment, and cognitive or speech difficulties. In the United States, more than 80,000 patients each year experience an acute ICH, and the condition contributes substantially to years of life lost, particularly among adults aged 35-65.
Despite decades of research, treatment options for ICH remain limited. Standard medical management focuses on blood pressure control, reversal of coagulopathy, prevention of hematoma expansion, and management of intracranial pressure. Traditional open craniotomy has not consistently improved functional outcomes and carries risks such as infection, rebleeding, and prolonged recovery. As a result, interest has grown in minimally invasive surgical (MIS) techniques designed to remove the hematoma while minimizing damage to surrounding brain tissue.
Over the past two decades, several MIS approaches have been developed, including catheter-based aspiration with thrombolytics, neuroendoscopic evacuation, minimally invasive puncture and drainage, and navigated trans-sulcal parafascicular surgery using tubular retractors. These techniques aim to reduce surgical trauma, improve hematoma evacuation, and limit secondary brain injury caused by inflammation, oxidative stress, and perihematomal edema.
Recent randomized trials have provided important insights into the potential benefits of MIS. The MISTIE III trial demonstrated procedural safety and suggested improved outcomes in patients who achieved substantial hematoma reduction. The ENRICH trial showed that early minimally invasive parafascicular surgery improved functional outcomes at 180 days for patients with lobar ICH and reduced mortality, ICU stay, and serious adverse events. Other trials, including MIND and SWITCH, have contributed additional data on safety, short-term disability, and the potential role of MIS in deep hemorrhages. Updated guidelines from the European Stroke Organization and the American Heart Association now support consideration of MIS for selected patients with supratentorial ICH.
Although evidence is growing, real-world practice varies widely due to differences in patient selection, surgical expertise, device availability, and institutional protocols. Randomized trials often include highly selected populations, limiting generalizability. There is a need for large-scale, prospective, real-world data to better understand how MIS is used across diverse clinical settings and to identify which patients benefit most.
The Rapid Evacuation and Access of Cerebral Hemorrhage (REACH) Registry is designed to address these gaps by prospectively collecting standardized data on patients undergoing MIS evacuation for spontaneous supratentorial ICH. The registry will capture patient demographics, comorbidities, hematoma characteristics, surgical techniques, timing of intervention, degree of hematoma evacuation, and clinical outcomes including mortality, complications, and functional status. By aggregating real-world data across multiple centers, the registry aims to evaluate the safety and effectiveness of different MIS approaches, identify predictors of favorable recovery, and support ongoing improvements in clinical practice.
Ultimately, the REACH Registry seeks to advance evidence-based care for patients with ICH, inform future clinical trials, and contribute to the refinement of national and international treatment guidelines
Subjects with acute, spontaneous supratentorial intracerebral hemorrhage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Surgical A: Endport evacuation (i.e., MIPS via BrainPath or similar device) * Surgical B: Endoscopic evacuation * Surgical C: Catheter-based evacuation * Surgical D: Other minimally invasive surgical techniques involving clot evacuation
No minimally invasive surgical hematoma evacuation performed; n=300 total, capped across 20 sites; may include patients undergoing decompressive hemicraniectomy or other standard medical/surgical approaches): * Basal Ganglia Controls (\>50% IVH or ICH volume ≥80 mL; n=100) * Lobar Controls (ICH volume ≥80 mL; n=100) * Primary Thalamic Controls (n=100) * ENRICH Trial Controls (ABG and lobar locations; n=150) * REACH Trial Controls (ABG location; n=maximum 300)
Modified Rankin Scale (mRS) at 180 Days
Functional outcome will be assessed using the modified Rankin Scale (mRS), a 7-level ordinal scale ranging from 0 (no symptoms) to 6 (death). The primary endpoint evaluates real-world functional recovery following minimally invasive surgery (MIS) for acute supratentorial ICH. Structured interview performed in person or via telephone by trained study personnel; audio-recorded and centrally adjudicated.
Time frame: Day 180 from baseline (±14 days)
30-Day Mortality
All-cause mortality within 30 days of the initial hemorrhage.
Time frame: Day 30 (±7 days)
modified Rankin Scale (mRS) at Additional Time Points
The endpoint evaluates real-world functional recovery following minimally invasive surgery (MIS) for acute supratentorial ICH. Collected over phone or in-person via structured interview.
Time frame: Day 7, 30, 90, 180, 365
Post-Operative Infection or CSF Leak
Incidence of surgical site infection or cerebrospinal fluid leak.
Time frame: Baseline through Day 365
Quality of Life (EQ-5D-5L)
The EQ-5D-5L assesses health status across five dimensions: * Mobility * Self-care * Usual activities * Pain/discomfort * Anxiety/depression Each dimension has five levels (no problems, slight problems, moderate problems, severe problems, extreme problems), allowing patients to describe their health using a five-digit health state (e.g., 11223). Patients also complete a Visual Analogue Scale (VAS) rating their overall health from 0 (worst imaginable) to 100 (best imaginable)
Time frame: Day 7, 30, 90, 180, 365
Follow-Up Neuroimaging (24-Hour)
Assessment of hematoma evacuation effectiveness and residual volume.
Time frame: Within 24 hours post-procedure
In-Hospital Mortality
All-cause mortality occurring during the initial hospitalization.
Time frame: From date of enrollment through the date of hospital discharge (upto 14 days)
Change in Hematoma Volume
Difference between initial hematoma volume and follow-up neuroimaging volume, assessed centrally by the Neuroimaging Core Lab.
Time frame: Baseline to follow-up imaging (within first 10 days)
Post-Operative Rebleeding With Neurologic Deterioration (Surgery Group Only)
Rebleeding is defined as hematoma growth on follow-up imaging accompanied by neurologic decline (National Institute of Health Stroke Scale (NIHSS) increase ≥4 or Glasgow Coma Score (GCS) decrease ≤2)
Time frame: Baseline through Day 10
Time to Intervention
Time from ictus (symptom onset) to MIS procedure.
Time frame: From time of enrollment through the time of procedure (upto 100 days)
Surgical Complications
Any intraoperative or postoperative complication related to Minimally invasive surgery (MIS) technique, including device-related events.
Time frame: Baseline through Day 365
Residual Post-Operative Hemorrhage Volume
Quantification of remaining hematoma volume after MIS.
Time frame: Post-operative imaging (≤10 days)
Serious Adverse Events (SAEs)
SAEs include events resulting in death, life-threatening conditions, hospitalization, disability, or events requiring medical/surgical intervention.
Time frame: Baseline through Day 365
Hospital Length of Stay
Total number of days from hospital admission to discharge.
Time frame: From date of enrollment to the date of discharge (upto 4 weeks or more)
Decompressive Hemicraniectomy
Receipt of decompressive hemicraniectomy during the initial hospitalization.
Time frame: Baseline through discharge (upto 100 days or more)
ICU Length of Stay
Number of days from ICU admission to ICU discharge.
Time frame: From date of enrollment to the date of ICU discharge (upto 100 days or more)
Duration of Mechanical Ventilation
Total duration of mechanical ventilation during the initial hospitalization.
Time frame: Time from enrollment to the time mechanical ventilation was stopped (upto 100 days or more)
Plan to share: Yes — Data will be shared for special requests. REACH Trial must have the primary paper published, and the first 3 papers from the registry must be complete before the data becomes available for sharing.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Access criteria: Request to REACH Registry Executive Committee and/or REACH Registry Publications and Data Management Committee (PDMC)
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jun 2033, 82 months after the start.
Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 82 months is above that.
Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.